Smith Stan's Form 4 filing
MAIA Biotechnology, Inc. (MAIA) · filed Jan 27, 2023
- Accession no.
- 0001127602-23-002395
- Filed
- Jan 27, 2023
- Trade date
- Jan 25-26, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $1.00K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Smith StanCIK 0001913199 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of The Stan V. Smith Trust Dated 1993 that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
Referenced by the price of 2 transactions in Table I.
- F2
The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.18 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
Referenced by the price of 1 transaction in Table I.